Signs of Sleep Apnoea: Symptoms and Treatment

Signs of sleep apnoea are often missed or mistaken for everyday tiredness, yet the condition affects a significant proportion of UK adults and carries serious health risks if left untreated. Sleep apnoea causes repeated interruptions to breathing during sleep, leading to symptoms such as loud snoring, gasping on waking, and persistent daytime sleepiness. Recognising the warning signs early is essential, as effective NHS treatments are available. This article explains the key signs to look out for, who is most at risk, how diagnosis works on the NHS, and what happens if the condition goes untreated.

What are the most common signs of sleep apnoea?

The most common signs are loud persistent snoring, repeated pauses in breathing, and gasping or choking on waking, alongside daytime symptoms including excessive sleepiness, morning headaches, and difficulty concentrating.

The most common signs of sleep apnoea include loud, persistent snoring, repeated pauses in breathing during sleep, and waking with a gasping or choking sensation. Sleep apnoea is a condition in which the upper airway repeatedly narrows or closes during sleep, causing brief interruptions to breathing that can occur dozens or even hundreds of times each night. The most frequently reported form is obstructive sleep apnoea (OSA), though central sleep apnoea, where the brain fails to send the correct signals to the breathing muscles, is also recognised.

Daytime symptoms are often just as telling as those that occur overnight. People with sleep apnoea commonly experience:

• Excessive daytime sleepiness, even after what feels like a full night in bed

• Morning headaches, which can be related to overnight changes in blood oxygen, carbon dioxide levels, and sleep fragmentation^[4][6]

• Difficulty concentrating or memory problems

• Irritability or low mood

• Dry mouth or sore throat on waking

• Nocturia (waking frequently to urinate)

Because many of these symptoms develop gradually, they are often attributed to stress, ageing or a busy lifestyle rather than a sleep disorder. A bed partner or family member may notice the breathing pauses or loud snoring before the person themselves does. If you or someone close to you recognises several of these signs together, it is worth discussing them with a GP, as sleep apnoea is both common and treatable. If excessive daytime sleepiness is affecting your ability to drive or carry out safety-critical tasks, stop driving and seek same-day advice from your GP or NHS 111.

Further information on symptoms and definitions is available from the NHS sleep apnoea pages and NICE guideline NG202 (Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in adults, 2021).^[1]

How do I know if my snoring is something more serious?

Snoring is more likely to indicate sleep apnoea if it is accompanied by witnessed breathing pauses, gasping episodes, or significant daytime sleepiness; an Epworth Sleepiness Scale score of 11 or above warrants further assessment.

Snoring that is accompanied by witnessed pauses in breathing, gasping or choking episodes, or significant daytime sleepiness is more likely to indicate sleep apnoea than simple snoring alone. Simple snoring, sometimes called primary snoring, occurs when soft tissue in the throat vibrates during sleep but does not cause the airway to close completely. It can be disruptive to a bed partner but does not carry the same health risks as obstructive sleep apnoea.

Several features suggest that snoring may be something more serious:

• Loud, irregular snoring that is punctuated by silences followed by a snort or gasp

• Witnessed apnoeas, where a partner observes you stop breathing for several seconds

• Waking unrefreshed despite spending seven or more hours in bed

• Falling asleep involuntarily during the day, for example while reading, watching television or, more dangerously, driving

• Snoring that has worsened alongside weight gain or a change in sleeping position

The Epworth Sleepiness Scale (ESS) is a simple questionnaire used in NHS practice to quantify daytime sleepiness, as referenced in NICE NG202. A score of 11 or above out of 24 suggests excessive daytime sleepiness and warrants further assessment.

If you are concerned that your snoring may be more than a nuisance, keep a brief sleep diary noting how often you wake, how rested you feel, and any symptoms your partner has observed, and bring this to your GP appointment.

Driving and the DVLA: If you feel sleepy at the wheel, do not drive. Under DVLA guidance (Assessing fitness to drive, sleep apnoea/OSA syndrome section), you must not drive if sleepiness impairs your ability to drive safely, and you must notify the DVLA if you are diagnosed with OSA syndrome that causes excessive daytime sleepiness. Group 2 licence holders (lorry and bus drivers) are subject to stricter standards and should seek specific advice from their GP and the DVLA. The relevant DVLA guidance is available at gov.uk.

Who is most at risk of developing sleep apnoea in the UK?

People who are overweight, male, or aged over 40 are at greatest risk, though anatomical features, alcohol use, smoking, and conditions such as hypothyroidism also increase susceptibility.

Obstructive sleep apnoea is significantly more common in people who are overweight or obese, in middle-aged and older adults, and in men, though it can affect people of any age, sex or body size. According to NHS guidance and NICE NG202, excess weight is one of the strongest modifiable risk factors because fatty tissue around the neck and throat can narrow the upper airway during sleep. A neck circumference greater than 43 cm in men or 40 cm in women is associated with increased risk, as used in validated pre-test probability tools such as the STOP-BANG questionnaire.^[1][6]

Other recognised risk factors include:

• Male sex: men are approximately twice as likely to develop OSA as pre-menopausal women, though the gap narrows after the menopause^[17][1]

• Age: prevalence increases with age, particularly from the forties onwards

• Anatomical features: a narrow airway, enlarged tonsils or adenoids, a recessed jaw, or a large tongue can all contribute

• Alcohol and sedative use: these relax the throat muscles and worsen airway collapse

• Smoking: associated with airway inflammation and increased OSA risk

• Nasal congestion: chronic blockage from allergies or a deviated septum increases the effort needed to breathe during sleep

• Family history: there is a genetic component to airway anatomy and obesity risk

• Certain medical conditions: hypothyroidism, acromegaly, and Down's syndrome are associated with higher rates of sleep apnoea^[1][6]

Children can also develop sleep apnoea, most commonly due to enlarged tonsils and adenoids, and the presentation in children may differ from adults, with hyperactivity and behavioural difficulties sometimes being more prominent than sleepiness. NHS guidance on paediatric sleep apnoea provides further detail on recognition and referral in this age group.

How is sleep apnoea diagnosed on the NHS?

Diagnosis begins with a GP assessment using tools such as the Epworth Sleepiness Scale, followed by a home sleep study that calculates the Apnoea-Hypopnoea Index; an AHI of 15 or above indicates moderate to severe OSA.

Sleep apnoea is diagnosed on the NHS through a combination of clinical assessment and a sleep study, which may be carried out at home or in a specialist sleep centre. The diagnostic pathway typically begins with a GP appointment, where the doctor will review symptoms, take a history, and may use validated tools such as the Epworth Sleepiness Scale or the STOP-BANG questionnaire to assess the likelihood of OSA. Blood pressure, weight, and neck circumference are usually measured at this stage.

If OSA is suspected, the GP will refer the patient to a sleep clinic or respiratory medicine service. NICE guideline NG202 (2021) supports the use of home sleep studies as the first-line investigation for most adults with suspected OSA, as these are less disruptive and more cost-effective than in-laboratory polysomnography.^[2][1] A home sleep study typically involves wearing a small device overnight that records:

• Oxygen saturation (via a finger probe)

• Airflow through the nose and mouth

• Chest and abdominal movement

• Heart rate

• Body position

The results are used to calculate the Apnoea-Hypopnoea Index (AHI), which measures the average number of breathing interruptions per hour of sleep. In line with NICE NG202 and UK clinical practice, an AHI of 5 to 14 is classified as mild OSA, 15 to 29 as moderate, and 30 or above as severe. In-laboratory polysomnography, which records additional parameters including brain activity and limb movements, is reserved for cases where the diagnosis is uncertain or where another sleep disorder is suspected. Waiting times vary between NHS trusts, and your GP can advise on local pathways.

What happens if sleep apnoea is left untreated?

Untreated OSA significantly raises the risk of hypertension, stroke, heart failure, and type 2 diabetes complications, and causes daytime sleepiness that increases road traffic accident risk.

Untreated sleep apnoea is associated with a significantly increased risk of cardiovascular disease, including hypertension, heart attack, stroke, and atrial fibrillation, as well as impaired metabolic health and reduced quality of life. Each apnoea episode causes a brief drop in blood oxygen and a surge in stress hormones as the body rouses itself to restore breathing. Over months and years, these repeated physiological stresses place considerable strain on the heart and blood vessels. These associations are described in NICE NG202 and NHS guidance on OSA.

The health consequences of untreated OSA extend across multiple body systems:

• Cardiovascular: hypertension is present in a substantial proportion of people with OSA, and the condition is independently associated with increased risk of stroke and heart failure

• Metabolic: OSA is linked to insulin resistance and may worsen blood glucose control in people with type 2 diabetes^[10][11]

• Mental health: chronic sleep fragmentation contributes to depression, anxiety, and cognitive impairment

• Road safety: excessive daytime sleepiness substantially increases the risk of road traffic accidents. DVLA guidance states that you must not drive if sleepiness impairs your ability to drive safely, and you must notify the DVLA if diagnosed with OSA syndrome causing excessive daytime sleepiness. Group 2 licence holders face stricter requirements. If you feel sleepy at the wheel, stop driving and seek medical advice promptly

• Occupational: impaired concentration and reaction time can affect work performance and safety, particularly in roles involving machinery or shift work

Children with untreated sleep apnoea may experience difficulties with learning, behaviour, and growth. Effective treatment can reverse many of these consequences, and most people notice a meaningful improvement in daytime alertness and wellbeing within weeks of starting therapy. If you recognise these risks in yourself or a family member, contact your GP rather than waiting for symptoms to worsen.

What treatment options are available for sleep apnoea in the UK?

NICE NG202 recommends CPAP as the primary treatment for moderate to severe OSA, with mandibular advancement devices for milder cases, alongside lifestyle changes including weight loss and reducing alcohol intake.

The main NHS treatments for obstructive sleep apnoea are continuous positive airway pressure (CPAP) therapy, mandibular advancement devices, and lifestyle modification, with the choice depending on severity and individual circumstances. NICE NG202 recommends CPAP as the primary treatment for adults with moderate to severe OSA.^[1][5] It works by delivering a gentle, continuous stream of pressurised air through a mask worn during sleep, which acts as a pneumatic splint to keep the upper airway open. Most people find that daytime sleepiness improves considerably within the first few weeks of consistent CPAP use.

For people with mild to moderate OSA, or those who cannot tolerate CPAP, a mandibular advancement device (MAD) is a custom-fitted dental appliance that holds the lower jaw slightly forward during sleep, widening the airway. NICE NG202 supports MADs as an alternative to CPAP in appropriate patients. Both CPAP machines and MADs can be provided through NHS sleep services following a confirmed diagnosis.

Lifestyle changes are recommended alongside device therapy for most people and include:

• Weight loss, which can substantially reduce OSA severity in people who are overweight, with evidence supporting meaningful reductions in AHI with sustained weight reduction^[5][15]

• Reducing alcohol intake, particularly in the evening

• Stopping smoking

• Avoiding sedative medications where clinically possible

• Positional therapy for people whose OSA is predominantly worse when sleeping on their back

Surgical options, such as tonsillectomy (particularly in children with enlarged tonsils and adenoids) or procedures to address nasal obstruction, may be considered in selected cases where device therapy is not suitable or has not been effective. Indications are selective and are assessed on an individual basis by a specialist.

For people exploring how to access assessment and support, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations with prescriber review, which may be relevant where related health concerns such as weight management are part of the clinical picture. Suspected side effects from any prescribed treatment can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in adults (NG202).
2. NG202 Chapter 1: Obstructive sleep apnoea/hypopnoea syndrome.
3. NG202 Terms used in this guideline (AHI severity thresholds).
4. NG202 Rationale and impact.
5. NG202 Full guideline PDF.
6. Sleep apnoea.
7. Excessive sleepiness and driving.
8. Miscellaneous conditions: assessing fitness to drive.
9. Prevalence of silent atrial fibrillation and cardiovascular outcomes in obstructive sleep apnea (Højager et al.).
10. Obstructive sleep apnoea and type 2 diabetes mellitus (Aurora RN et al.).
11. Obstructive sleep apnoea and glucose dysregulation in type 2 diabetes: a systematic review of the literature. Frontiers in Medicine..
12. Impact of CPAP therapy on diabetes control in patients with OSA. Cureus..
13. Nocturia as a clinical marker of cardiovascular risk in obstructive sleep apnoea. Sleep Medicine..
14. Disease-related etiologies of nocturia: a focused literature review. Current Urology Reports..
15. GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials. Sleep & Breathing..
16. Efficacy of GLP-1 receptor agonists in treating obstructive sleep apnea: a systematic review and meta-analysis. Sleep & Breathing..
17. Prevalence and characteristics of positional sleep apnea in the HypnoLaus population-based cohort. Sleep Medicine..
18. Mandibular advancement devices for OSA: an alternative to CPAP (Francis CE et al.). 2021..

Frequently Asked Questions